TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04970069

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video on analgesic education
Description: A four minute video informing the patient about opioids.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Video on general perioperative education
Description: A four minute video informing the patient about general perioperative process.
Study: NCT05415488

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Online dietary group treatment
Description: Dietary advice will be given during one 90 minute online group session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online dietary group treatment
Description: Dietary advice will be given during one 90 minute online group session
Study: NCT05960838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasling® Quadrant
Description: Immobilization with the Ultrasling® Quadrant (DJO Global Switzerland Sàrl, Ecublens, Switzerland) shoulder brace after surgical treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bledsoe ARC®
Description: Immobilization with the Bledsoe ARC® (Breg Inc., Carlsbad, CA USA) brace after surgical treatment
Study: NCT05634330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise treatment
Description: core stabilization exercise
Study: NCT04940468

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet Intervention
Description: The dietary fiber intake target will be 19 g/d for ages 9-18 and females age 19 and older and 23g/d for males age 19 and older.
Study: NCT04903626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (GLE/PIB)
Description: Oral tablets
Study: NCT06158867

Intervention type: DEVICE
Intervention: FMD WK
Description: micro-needle patches containing active anti-wrinkle ingredients
Study: NCT06452771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-ANG3
Description: Administered subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-ANG3
Description: Administered subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PB)
Description: Administered SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PB)
Description: Administered SC injection
Study: NCT06225362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quatera 700
Description: Phacoemulsification device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Centurion
Description: Phacoemulsification device
Study: NCT05089370

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab
Description: Activation of the RIG-I innate immune pathway and increased expression of tumor antigens and pro-immune genes during Nivolumab treatment may enhance the frequency and activity of anti-tumor immune cells (CD4+ and CD8+ T-cells, NK cells) and reduce the frequency and activity of immunosuppressive cells (MDSCs, Tregs) (1-4), increasing the overall effectiveness and success of Nivolumab treatment. This pilot clinical trial will demonstrate whether combinatorial immunotherapeutic approaches that target epigenetic immune repression and RIG-I activity can favorably alter the tumor immune cell microenvironment and benefit mucosal melanoma patients.
Study: NCT06132178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (COMP360).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (COMP360).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated intermittent theta burst (aiTBS) rTMS treatment
Description: A form of non-invasive brain stimulation that delivers a series of quick magnetic pulses to the scalp and a portion of the brain. It will be targeted to a functional magnetic resonance imaging (fMRI) functional connectivity-guided personalized left dorsolateral prefrontal cortex target using neuronavigation and delivered over 10 sessions daily for 5 consecutive days at 90% of coil-to-target depth-corrected resting motor threshold.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated intermittent theta burst (aiTBS) rTMS treatment
Description: A form of non-invasive brain stimulation that delivers a series of quick magnetic pulses to the scalp and a portion of the brain. It will be targeted to a functional magnetic resonance imaging (fMRI) functional connectivity-guided personalized left dorsolateral prefrontal cortex target using neuronavigation and delivered over 10 sessions daily for 5 consecutive days at 90% of coil-to-target depth-corrected resting motor threshold.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose psilocybin
Description: A psychedelic drug found in certain mushrooms. It will be in a low-dose form of the experimental dose as a 1mg capsule of psilocybin (COMP360).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Low-dose psilocybin
Description: A psychedelic drug found in certain mushrooms. It will be in a low-dose form of the experimental dose as a 1mg capsule of psilocybin (COMP360).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment
Description: The sham version is meant to look and feel like the active SAINT rTMS, but the main difference is that the brain is not being stimulated like the active condition.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment
Description: The sham version is meant to look and feel like the active SAINT rTMS, but the main difference is that the brain is not being stimulated like the active condition.
Study: NCT05160701

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medherent
Description: Medherent is a telehealth adherence intervention platform designed for individuals with Serious Mental Illness living in the community. It is currently being used to dispense medication and monitor consumer adherence. It is a fully supported digital hub that is always on network connection and provides a cost- effective mechanism for increased care coordination through the Electronic Medication Record (EMR). The enhanced intervention will add collection of health data though Bluetooth connected devices, Telehealth medical visits and integrated algorithms that provide feed back to providers and consumers about health status.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medherent
Description: Medherent is a telehealth adherence intervention platform designed for individuals with Serious Mental Illness living in the community. It is currently being used to dispense medication and monitor consumer adherence. It is a fully supported digital hub that is always on network connection and provides a cost- effective mechanism for increased care coordination through the Electronic Medication Record (EMR). The enhanced intervention will add collection of health data though Bluetooth connected devices, Telehealth medical visits and integrated algorithms that provide feed back to providers and consumers about health status.
Study: NCT06112860

Intervention type: DEVICE
Group type: OTHER
Intervention: Over the counter hearing aid
Description: An over the counter hearing aid is a device that provides amplification appropriate for individuals with mild to moderate hearing loss. Participants will receive the devices with typical directions and have one scheduled remote visit one week after receiving devices with an audiologist.

Intervention type: DEVICE
Group type: OTHER
Intervention: Over the counter hearing aid
Description: An over the counter hearing aid is a device that provides amplification appropriate for individuals with mild to moderate hearing loss. Participants will receive the devices with typical directions and have one scheduled remote visit one week after receiving devices with an audiologist.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Communication Strategies Information/Counseling
Description: Communication Strategies provide information meant to help an individual compensate for hearing loss. The information provides tips both for the individual with hearing loss and for those communicating. People who choose not to pursue hearing aids will typically be given communication strategies information to help them manage their hearing loss. Participants will receive the counseling information in the mail and then have a 1 week follow-up appointment with an audiologist.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Communication Strategies Information/Counseling
Description: Communication Strategies provide information meant to help an individual compensate for hearing loss. The information provides tips both for the individual with hearing loss and for those communicating. People who choose not to pursue hearing aids will typically be given communication strategies information to help them manage their hearing loss. Participants will receive the counseling information in the mail and then have a 1 week follow-up appointment with an audiologist.
Study: NCT05526755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg/40 mg
Description: Participants will receive osimertinib (80 mg or 40 mg orally, once daily).
Study: NCT05973006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine
Description: Coformulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 µg antigen and 100 µg adjuvant per mL. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg antigen with 50 µg Matrix-M adjuvant.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
Description: A site-mixed bivalent vaccine prepared by combining 0.25 mL of NVX-CoV2373 and 0.25 mL NVX-CoV2601. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg total antigen (2.5 µg prototype antigen + 2.5 µg Omicron XBB.1.5 antigen) with 50 µg Matrix-M adjuvant.
Study: NCT06289400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic field application
Description: The applicator (Size: 15x15 cm) has placed 1-3 cm above the skin surface at the painful area. During the treatment, treatment has applied with ready-made protocols included in the device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Within the scope of conventional treatment, hotpack application, transcutaneous electrical stimulation (TENS), interferential current and ultrasound treatment modalities will be applied. In addition, strengthening exercises will be applied to the muscles around the hip and knee and stretching exercises will be applied to the short muscle groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Within the scope of conventional treatment, hotpack application, transcutaneous electrical stimulation (TENS), interferential current and ultrasound treatment modalities will be applied. In addition, strengthening exercises will be applied to the muscles around the hip and knee and stretching exercises will be applied to the short muscle groups.
Study: NCT06279312

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: consume 1 drink per day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Adaptogen Elixir drink
Description: consume 1 drink per day for 4 weeks
Study: NCT06158022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: An initial infusion dose of prophylactic phenylephrine (0.5 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.1 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT06559462

Intervention type: OTHER
Group type: OTHER
Intervention: Focus Group
Description: Open-ended group discussion of potential nudges to elicit constructive feedback on nudge development.

Intervention type: OTHER
Group type: OTHER
Intervention: Focus Group
Description: Open-ended group discussion of potential nudges to elicit constructive feedback on nudge development.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discrete Choice
Description: Survey involving choice between two potential nudges to elicit feedback on which nudge version is considered superior.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discrete Choice
Description: Survey involving choice between two potential nudges to elicit feedback on which nudge version is considered superior.
Study: NCT06119854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attitudinal inoculation
Description: A brief video focused on bolstering resistance to mis/disinformation about the COVID vaccine. Participants will receive two messages via text or email (1 and 3 days after the inoculation intervention). These messages will include reminders to get vaccinated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy-informed intervention
Description: A brief video using a CBT-informed approach and focused on addressing barriers to COVID-19 vaccination. Participants will receive two messages via text or email (1 and 3 days after the inoculation intervention). These messages will include reminders to get vaccinated.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional public health messaging
Description: A brief video conveying conventional public health messaging adapted from a review of public health public service announcements with no inoculation messaging. Participants will receive two messages via text or email (1 and 3 days after the inoculation intervention). These messages will include reminders to get vaccinated.
Study: NCT04734860

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-AMG
Description: COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent solution
Study: NCT04840017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation exercise
Description: Rehabilitation exercise of intrinsic foot muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation exercise
Description: Rehabilitation exercise of intrinsic foot muscles
Study: NCT06101082

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous infusion anti-HER2-CAR-T cell
Description: Anti-HER2-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 1×10\^6 CAR-T cells/kg, 3×10\^6 CAR-T cells/kg, and 1×10\^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.
Study: NCT06356948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (TXA)
Description: Study drug administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (TXA)
Description: Study drug administration
Study: NCT05199766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor 1500 mg oral per day (GBT440) for 48 weeks in patients with sickle-cell disease
Description: This is an open-label, single-arm, single-stage phase II trial of voxelotor in patients with sickle-cell disease. Voxelotor 500mg tablets. Voxelotor will be administered as 500mg tablets orally once daily. The participant should always take all 3 tablets in a row at the same time each day, unless the study doctor has instructed them to adjust the dose.
Study: NCT05530343

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Seattle protocol
Description: Participants undergo 4-quadrant biopsies with standard biopsy forceps taken at 2 cm intervals. For participants undergoing a confirmatory endoscopy for cases in which discordant results are noted (WATS3D positive for dysplasia/cancer and Seattle biopsy negative for dysplasia/cancer), repeat biopsies will be taken at 1 cm intervals along with target biopsies from any visible lesions.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Seattle protocol
Description: Participants undergo 4-quadrant biopsies with standard biopsy forceps taken at 2 cm intervals. For participants undergoing a confirmatory endoscopy for cases in which discordant results are noted (WATS3D positive for dysplasia/cancer and Seattle biopsy negative for dysplasia/cancer), repeat biopsies will be taken at 1 cm intervals along with target biopsies from any visible lesions.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: WATS3D brushings
Description: Participants undergo 2 WATS3D biopsies of every 5 cm segment of Barrett's esophagus, starting from the gastroesophageal junction and moving proximally through the entire segment of Barrett's.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: WATS3D brushings
Description: Participants undergo 2 WATS3D biopsies of every 5 cm segment of Barrett's esophagus, starting from the gastroesophageal junction and moving proximally through the entire segment of Barrett's.
Study: NCT05483803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adhera® Caring digital intervention for Type 1 Diabetes
Description: The Adhera® Caring is a mobile based personalized digital intervention for caregivers, lasting for 1 or 3 months (depending on the sub-study).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adhera® Caring digital intervention for Type 1 Diabetes
Description: The Adhera® Caring is a mobile based personalized digital intervention for caregivers, lasting for 1 or 3 months (depending on the sub-study).
Study: NCT04835649

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Both groups will receive exercise-based training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both groups will receive exercise-based training
Study: NCT06219993

Intervention type: PROCEDURE
Intervention: robot-assisted modified Kasai portoenterostomy
Description: 1. A 1.0 cm incision was made around the umblilicus for the camera port. 1.Firstly, the Exploring hepatic subcapsular spider-like telangiectasis (HSST) sign at the surface of the liver, and indocyanine green (ICG) cholangiography were observed to confirm the BA diagnosis.~2. dissecting forceps and electric scissors were applied to dissociate the atresia bile ducts and lymph nodes in portal hepatis. Exposed the hepatic artery and portal vein. All portal vein tributaries that drain into the fibrous cone were coagulated by bipolar coagulation to expose the portal plate for resection. With electric scissors help, the fibrous plate was horizontally cut from the middle of the portal plate and transected from to the left and to the right sides which was the Glissonian systems enter the liver parenchyma until see the bile outflow by verified by ICG. The opening of microbile ducts and abundant bile outflow were clearly visible under 10× camera of Da Vinci robot.

Intervention type: PROCEDURE
Intervention: traditional open Kasai portoenterostomy
Description: Dissecting forceps and electric scissors were applied to dissociate the atresia bile ducts and lymph nodes in portal hepatis. Exposed the hepatic artery and portal vein. All portal vein tributaries that drain into the fibrous cone were coagulated by bipolar coagulation to expose the portal plate for resection. With scissors help, the fibrous cone of the hilar region was transected from left to right (the level of transection depends on adequate bile outflow).
Study: NCT05732974

Intervention type: OTHER
Intervention: Resected non small cell lung cancer
Description: plasma sample, tissue sample and computed tomography scan images
Study: NCT04591041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HoloSIM Software via Hololens 2
Description: Medical students will train via a mixed reality simulated crisis scenario using the HoloSIM software on the Microsoft Hololens 2
Study: NCT05902455

Intervention type: PROCEDURE
Intervention: Punch biopsy
Description: Punch biopsy of oral squamous cell carcinoma tumor and a control biopsy of healthy oral mucosa are collected during primary tumor excision surgery from each recruited patient.
Study: NCT04475991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc + Currently used therapy
Description: Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)
Study: NCT04591041

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training by Mannequin Based Simulation
Description: Medical students will train a via traditional mannequin based medical crisis scenario
Study: NCT04475991

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Curently used therapy for COVID-19 non-critical patients
Description: Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga
Study: NCT05370755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-189
Description: Administered orally
Study: NCT04475991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir + Currently used therapy
Description: Favipiravir tablets 200 mg. given orally for a 7 day period. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga).
Study: NCT05614557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratacel
Description: Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratamed
Description: Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
Study: NCT05696795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Description: Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of sarcoidosis.
Study: NCT04693689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RNA vaccine
Description: We elicit subjects' willingness to receive RNA COVID-19 vaccine